BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16203818)

  • 1. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
    Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
    Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X
    Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lindén O; Kurkus J; Garkavij M; Cavallin-Ståhl E; Ljungberg M; Nilsson R; Ohlsson T; Sandberg B; Strand SE; Tennvall J
    Cancer Biother Radiopharm; 2005 Aug; 20(4):457-66. PubMed ID: 16114994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Nilsson R; Sandberg BE; Brechbiel M
    Bioconjug Chem; 2002; 13(5):1079-92. PubMed ID: 12236790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
    Wang Z; Garkavij M; Ohlsson T; Strand SE; Sjögren HO; Tennvall J
    Cancer Biother Radiopharm; 2003 Jun; 18(3):365-75. PubMed ID: 12954123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
    Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
    Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.
    Al-Ejeh F; Darby JM; Thierry B; Brown MP
    Nucl Med Biol; 2009 May; 36(4):395-402. PubMed ID: 19423007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
    Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
    J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.
    DeNardo SJ; DeNardo GL; Yuan A; Richman CM; O'Donnell RT; Lara PN; Kukis DL; Natarajan A; Lamborn KR; Jacobs F; Siantar CL
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3938S-44S. PubMed ID: 14506192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi) therapy.
    Junghans RP; Dobbs D; Brechbiel MW; Mirzadeh S; Raubitschek AA; Gansow OA; Waldmann TA
    Cancer Res; 1993 Dec; 53(23):5683-9. PubMed ID: 8242624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
    Grünberg J; Jeger S; Sarko D; Dennler P; Zimmermann K; Mier W; Schibli R
    PLoS One; 2013; 8(4):e60350. PubMed ID: 23565233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
    Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
    Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging.
    Smith-Jones PM; Solit DB
    Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
    Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
    Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.